Last reviewed · How we verify
Unasyn
At a glance
| Generic name | Unasyn |
|---|---|
| Also known as | ampicillin, sulbactam |
| Sponsor | Stanford University |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Short Versus Standard of Care Antibiotic Duration for Children Hospitalized for CAP (PHASE4)
- Cost Effectiveness in Alveolar Bone Grafting in Patients With Cleft Lip and Palate (PHASE4)
- Therapeutic Options for CRAB (PHASE4)
- Cefiderocol and Ampicillin-sulbactam vs. Colistin +/- Meropenem for Carbapenem Resistant A. Baumannii (PHASE4)
- The Evaluation of Postoperative Antibiotics in Non-Infected Mandible Fractures (PHASE1)
- Patients Response to Early Switch To Oral:Osteomyelitis Study (EARLY_PHASE1)
- Noninferiority Comparison of Prophylactic Open Fracture Antimicrobial Regimens (PHASE4)
- Ampicillin / Sulbactam vs. Ampicillin / Gentamicin for Treatment of Chorioamnionitis (PHASE2, PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Unasyn CI brief — competitive landscape report
- Unasyn updates RSS · CI watch RSS
- Stanford University portfolio CI